Company InformationPattern Bioscience was founded on April 2016. The company is based in Austin, TX, USA . The number of employees in Pattern Bioscience is less than 50. Pattern bioscience is a privately held in vitro diagnostics company founded in 2016 to help combat the problem of antibiotic resistance.
Here is how Pattern Bioscience describes itself: "Pattern Bioscience will deliver the fastest ever phenotypic ID/AST"
Funding & investorsPattern Bioscience has received 2 rounds of venture funding. The total funding amount is around $25.5M.
- CARB-X (Accelerator)
Similar Companies [beta]
Active Venture Investors
Pattern Bioscience - Blog
- Building a Great Place to Work
- Pattern Raises Additional $9M to Fast-track New Technology for the Fight Against Antibiotic Resistance
- Pattern Secures $13M in Development Funding
- Klaris Named Finalist in AMR Diagnostic Challenge
- Klaris Diagnostics Secures $3.75 Million to Help Hospitals Fight Superbugs
Pattern recently interviewed Cindy Lopez, Director of People and Culture, about building a great place to work—both during these challenging times and beyond. Let’s start by giving everyone a little background info on your professional journey. I started with a degree in accounting, believe it or not, and went from there. My first role in […]The post Building a Great Place to Work appeared first on Pattern Bioscience.
Led by Illumina Ventures, the Series B-1 round will accelerate development and validation of transformational bacterial testing technology AUSTIN, Texas, July 14, 2020 – Pattern Bioscience, Inc. today announced $9M in additional funding to accelerate the development and clinical validation of its Digital CultureTM rapid bacterial identification and susceptibility testing (ID/AST) technology. Illumina Ventures led […]The post Pattern Raises Additional $9M to Fast-track New Technology for the Fight Against Antibiotic Resistance appeared first on Pattern Bioscience.
$6.8M CARB-X award plus $6.4M Series B led by Omnimed will help bring new technology to the fight against drug resistance. AUSTIN, Texas, February 4, 2020 – Pattern Bioscience, Inc., formerly operating as Klaris Diagnostics, today announced $13M in funding for the development of its Digital CultureTM technology, a rapid bacterial identification and susceptibility testing (ID/AST) […]The post Pattern Secures $13M in Development Funding appeared first on Pattern Bioscience.
Klaris has been selected as a finalist in the AMR Diagnostics Challenge federal prize competition, and will receive $100,000 to further develop its rapid ID/AST technology. The Challenge is a joint effort between the National Institutes of Health and the HHS Office of the Assistant Secretary for Preparedness and Response (ASPR) in support of the National […]The post Klaris Named Finalist in AMR Diagnostic Challenge appeared first on Pattern Bioscience.
Series A Financing Led by Omnimed Capital Austin, Texas, May 17, 2018 – Klaris Diagnostics, an in vitro diagnostics company focused on simplifying antibiotic selection for drug-resistant infections, today announced the completion of a $3.75 million Series A investment round, led by Omnimed Capital. Proceeds from the round will support additional development of the […]The post Klaris Diagnostics Secures $3.75 Million to Help Hospitals Fight Superbugs appeared first on Pattern Bioscience.